Document is current
Any future updates will be listed below
-
Authors
Chen, Hua-Jun
Tu, Hai-Yan
Hu, Yanping
Fan, Yun
Wu, Guowu
Cang, Shundong
Yang, Yi
Yang, Nong
Ma, Rui
Jin, Gaowa
Xu, Ximing
Liu, Anwen
Tang, Shubin
Cheng, Ying
Yu, Yan
Xu, Chong-Rui
Zhou, Qing
Wu, Yi-Long
- License Information
-
More Information
Article History
Received: 24 October 2024
Accepted: 23 December 2024
First Online: 5 January 2025
Declarations
:
: The study protocol was approved by the institutional review board (IRB) of each participating center. The IRB approval number in leading site Guangdong Lung Cancer Institute was 2018–375 H, and all patients provided written informed consent prior to participation. The study was conducted according to the principles of the Declaration of Helsinki and Good Clinical Practice requirements.
: Not applicable.
: Yi-Long Wu declares advisory services for AstraZeneca, Boehringer Ingelheim, Novartis, and Takeda; speaker fees from AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Pfizer, Roche, and Sanofi; and grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Hengrui, and Roche outside the submitted work. The remaining authors declare no conflict of interest.
